Engineers have developed a lipid nanoparticle (LNP) that delivers mRNA therapeutic to the placenta to treat pre-eclampsia in mice with human trials on the horizon. Penn Engineers have made a critical ...
For FY 2026, the company is targeting up to 10% growth over its 2025 revenue. ・Moderna’s Q1 net product sales rose on ...
A growing list of editing tools can be used to make small changes to the genetic code, tweaking key nucleotides to address the underlying causes of diseases. But bigger edits are often needed, and ...
A team of researchers has uncovered a key cellular mechanism that affects the function of mRNA vaccines and therapeutics. Their study provides the first comprehensive understanding of how mRNA ...
Delivering babies early, when possible, is currently the only way to deal with the common pregnancy complication pre-eclampsia. But the condition has now been successfully treated in mice by ...
Messenger Ribonucleic Acid (mRNA) vaccines gained global recognition during the Coronavirus Disease 2019 (COVID-19) pandemic, proving their value through rapid development, high efficacy, and broad ...
Bivalent EABR mRNA boosters broaden neutralizing responses to Omicron subvariants by promoting diverse receptor-binding domain epitope targeting, although antibody responses remain partially shaped by ...
Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV prefusion F glycoprotein, is under ...
Penn Engineers have made a critical breakthrough that bridges a major healthy equity gap for pregnant people with pre-eclampsia, a condition that arises due to insufficient blood flow to the placenta ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results